NCT07276360 2026-03-27
HypoRTCx-UG
Uganda Cancer Institute
Phase 2 Recruiting
Clinical Trials
15 trialsNCT03753659 2026-03-23
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT00525720 2026-03-09
Brachytherapy for Prostatic Carcinoma Patients
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01946529 2026-02-23
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT05320406 2026-02-12
REVELUTION
Emory University
Phase 2 Active not recruiting
NCT04395079 2026-02-09
Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT06331468 2025-12-26
Hypofractionated Radiochemotherapy
University of Kentucky
Phase 2 Recruiting
NCT01871766 2025-12-17
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT07232654 2025-12-01
Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05100472 2025-11-04
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04253483 2025-09-17
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT07152678 2025-09-03
BRIGHT-ESCC
National Taiwan University Hospital
Phase 2 Recruiting
NCT06023641 2025-08-19
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT02635360 2025-07-03
Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
University of Virginia
Phase 2 Completed